Trade deal in focus. Notwithstanding the 90-day truce on tariff escalation, it is still a 50/50 if there will be a “Big Beautiful Deal” between the US and China. The US is steadfast in wanting to cap China’s growth and restricting her access to the latest technology, while China is making a firm stand on its economic rights. We expect that higher US tariffs on Chinese goods are unavoidable, likely closer to the 60% mark, if Trump were to be seen making a credible move to onshore production in ...
GREATER CHINA Strategy Alpha Picks: June Conviction Calls: Add Prudential and Sino Biopharm to our BUY list. Take profit on SHKP and Trip.com. INDONESIA Strategy Alpha Picks: Good Performances In May: Good performances from most with the exception of GOTO and BUKA. MALAYSIA Strategy Alpha Picks: Raising Emphasis On Infrastructure Plays: Our May 25 Alpha Picks outperformed with resounding success. June 25 picks: Duopharma, Eco World, Gamuda, Hume Cement, IJM, MYEG, Northeast Group. SINGAPORE S...
TCOM’s 1Q25 earnings were better than expected. 1Q25 net revenue rose 16.2% yoy to Rmb13.9b, in line with consensus estimates. Non-GAAP net profit grew 3.3% yoy to Rmb4.2b, beating consensus forecasts by 9%. Net margin shrank 4ppt yoy to 30.3%, better than consensus estimates. TCOM guided a 2Q25 revenue growth of 12-17% yoy to Rmb14.6b, in line with expectations. Maintain BUY with a slightly higher target price of HK$635.00 (US$82.00).
KEY HIGHLIGHTS Results Alibaba Health Information Technology (241 HK/BUY/HK$4.89/Target: HK$6.20) FY25 revenue grew 13.2% yoy, while adjusted net profit surged 35.6% yoy, in line with our and market’s estimates. Ali Health guides FY26 revenue and adjusted net profit growth of 5-10% and 10-20% yoy respectively. We lower our FY26 revenue and earnings estimates, but still expect robust adjusted net profit CAGR of 20% for FY26-28 on an improving product mix for the direct sales business and contin...
What’s new: Trip.com’s reported 1Q25 revs that were in-line consensus and our expectations. Travel demand remains resilient as TCOM continues to gain market share in both domestic and international segments. We maintain our PT at USD75. Analysts: Jin Yoon
The HSI and MSCI China index fell 4.3% mom and 5.2% mom respectively in April, driven by Trump’s tariff announcements in early-April and fears of a potential global recession. Due to the ongoing external uncertainties, we will maintain our exposure to domestic policy beneficiaries and defensive sectors. New additions to our BUY list are Alibaba, Innovent, Shuanghuan, and Trip.com, and we take profit of CR Land and JBM Healthcare.
GREATER CHINA Strategy Alpha Picks: May Conviction Calls: Add Alibaba, Innovent, Shuanghuan, Trip.com to our BUY list. Take profit on JBM Healthcare and CR Land. INDONESIA Strategy Alpha Picks: Outperformance In Apr 25: Remove ICBP, EXCL and MIKA; add BBTN and GOTO. MALAYSIA Strategy Alpha Picks: Capitalising On Sentiment Turnaround: Our Apr 25 Alpha Picks underperformed. May 25 picks: Duopharma, Gamuda, IJM, IOI Properties, TIME dotCom, MYEG, Nationgate, Northeast Group and RHB Bank. SINGAPO...
GREATER CHINA Strategy Alpha Picks: May Conviction Calls Add Alibaba, Innovent, Shuanghuan, Trip.com to our BUY list. Take profit on JBM Healthcare and CR Land. Sector Aviation Airlines: 1Q25 results below expectations. Weak fuel prices to support full-year performance. Maintain UNDERWEIGHT. INDONESIA Strategy 1Q25 Results Recap ...
We saw continuous vitality in cultural and tourism consumption based on 1Q25 travel data and Labour Day travel data projections. Key travellers’ preference trends during Labour Day 2025 will be long-haul travel, inbound tourism and county-level travel. With favourable policy support such as the implementation of "instant tax refunds" for outbound travel, we expect to see promising revenue and earnings growth from OTA companies in 1H25. Maintain OVERWEIGHT.
Chinese internet companies’ share prices have dropped 10-30% mtd following the implementation of incremental tariffs from the US. Chinese internet companies have limited business exposure to the US except for PDD’s Temu. However, the 34% tariffs announced by China on all US imports could have potential implications for China mega-caps’ AI capex in relation to US chip imports. We prefer domestic-focused plays which stand to benefit from domestic policy stimuli, with Southbound inflow to be a key ...
GREATER CHINA Sector Internet Navigating headwinds and uncovering opportunities upon tariff pressures. INDONESIA Update Erajaya Swasembada (ERAA IJ/BUY/Rp348/Target: Rp480) Iphone 16 series to be available in 2Q25. Maintain BUY. MALAYSIA Update Matrix Concepts Holdings (MCH MK/BUY/RM1.27/Target: RM1.66) We view the RPT deal as fair and strategic as the acquisition allows Matrix to see faster ro...
GREATER CHINA Strategy Alpha Picks: April Conviction Calls: Add CR Beer, Desay, JBM Healthcare, JD Logistics, Minth, WuXi App Tech and Xiaomi Corp to our BUY list. Take profit on AIA, Hansoh Pharma, JD and Zijin Mining. INDONESIA Strategy Alpha Picks: Outperform In Mar 25: Remove BBNI, BBRI, ASII, JSMR and KLBF; add BBCA, ICBP, ERAA and BUKA. MALAYSIA Strategy Alpha Picks: Pockets of Opportunities: Our Mar 25 Alpha Picks outperform. Apr 25 picks: Alpha IVF, Duopharma, IJM, IOI Properties, TIME...
GREATER CHINA Strategy Alpha Picks: March Conviction Calls: Add Geely, JD, SHKP and Zijin Mining to our BUY list. Take profit on CATL, Desay, JD Logistics, Mengniu, Plover Bay and Tencent. INDONESIA Strategy Alpha Picks: Underperformance In Feb 25: Our picks are BBNI, BBRI, MIKA, EXCL, KLBF, JSMR and ASII. MALAYSIA Strategy Alpha Picks: Unprecedented Combo Of Disappointments: Our Feb 25 Alpha Picks sorely underperformed. Mar 25 picks: 99SpeedMart, Alpha IVF, KPJ Healthcare, MrDIY, MYEG, RHB Ba...
4Q24 results were better than expected. 4Q24 net revenue rose 23.5% yoy to Rmb12.8b, in line with consensus estimates. Non-GAAP net profit grew 13.6% yoy to Rmb3b, beating consensus forecasts by 6%. Net margin shrank 2ppt yoy to 23.8%, in line with consensus estimates. TCOM guided 1Q25 revenue growth of 14-19% yoy to Rmb13.8b, in line with consensus estimates. Maintain BUY with a lower target price of HK$630.00 (US$81.00).
KEY HIGHLIGHTS Results Trip.com (9961 HK/BUY/HK$462.00/Target: HK$630.00) 4Q24 results were better than expected. 4Q24 net revenue rose 23.5% yoy to Rmb12.8b, in line with consensus estimates. Non-GAAP net profit grew 13.6% yoy to Rmb3b, beating consensus forecasts by 6%. Net margin shrank 2ppt yoy to 23.8%, in line with consensus estimates. TCOM guided 1Q25 revenue growth of 14-19% yoy to Rmb13.8b, in line with consensus estimates. Maintain BUY with a lower target price of HK$630.00 (US$81.00...
REGIONAL Sector Plantation Guest speakers at our Palm Oil Seminar 2025 flag diverging palm production prospects between Malaysia and Indonesia, alongside downside risks to CPO prices. GREATER CHINA Results Trip.com (9961 HK/BUY/HK$462.00/Target: HK$630.00) 4Q24: Earnings beat; continuous efforts in international expansion. INDONESIA Small/Mid Cap Highlights Bumi Resources Minerals (BRMS IJ...
What’s new: Trip.com’s reported 4Q24 revs that were above consensus and our expectations. Travel demand during/post-CNY has remained resilient where TCOM could further gain market shares in both domestic and international markets. Margins could be adversely impacted by rev mix shift towards the pure international market segment. We maintain our PT at USD75. Analysts: Jin Yoon
Based on our data, TCOM is set to deliver strong 4Q2024 results, exceeding market expectations, with Accommodation and Transportation Revenue growth serving as the primary drivers of its performance. Coupled with additional contributing factors, the company’s solid trajectory underscores its ability to capitalize on the recovery in the global travel industry. While the short-term drivers are promising, the long-term outlook is equally compelling. As younger travelers fuel demand across high-grow...
We saw resilient enthusiasm for travel during the Spring Festival 2025, with a 6% yoy growth in the number of trips bolstered by domestic and cross border travel demand. We expect OTA companies’ earnings growth in 2025 to be anchored by cost optimisation with AIGC integration and lower-tier cities penetration, but offset by normalising airfare trends coupled with moderating hotel ADR (yoy decline). Maintain OVERWEIGHT.
GREATER CHINA Strategy Alpha Picks: February Conviction Calls: Add AIA, CR Land, Haier and Han’s Laser to our BUY list. Take profit on Crystal, Geely, Trip.com and Weimob. INDONESIA Strategy Alpha Picks: Slight Underperformance In Jan 25: Our picks are ISAT, KLBF, BMRI, BBRI, EXCL, CTRA, JSMR, BBNI and ASII. MALAYSIA Strategy Alpha Picks: Spotlight On The Upcoming Results Winners: Our Alpha Picks outperformed in Jan 25. Feb 25 picks: Gamuda, GENM, Kossan, MrDIY, MYEG, Pekat, RGB, RHB Bank, VSI...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.